Bemiparin
PreclinicalSmall molecule
Bemiparin is one of 20 small molecule programs targeting Venous Thromboembolism. It is currently in Preclinical.
1
Indications
14
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Venous Thromboembolism
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Lovenox
SanofiApproved
Xarelto
WWim Janssens
Approved
Savaysa
Daiichi SankyoApproved
Bayer Aspirin
BayerApproved
Crestor
AstraZenecaApproved
Coumadin
AAbbott
Approved
Colcrys
Jazz PharmaceuticalsApproved
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Neoral
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Low Molecular Weight Heparin2 trials
Prophylaxis2 trials
Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)
Terminated·—·Phase 3·NCT00311896·402 enrolled
COVID-191 trial
7 more indications
Small Cell Lung Carcinoma1 trial
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Terminated·—·Phase 2·NCT00324558·39 enrolled
Renal insufficiency1 trial
Safety and Efficacy1 trial
Venous Thromboembolism1 trial
Diabetic Foot1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bemiparin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details